

# Pharmaceutical Anti-Counterfeiting

*Combating the Real Danger  
from Fake Drugs*

**Mark Davison**

# Contents

## PREFACE

xxi

## ACKNOWLEDGMENTS

xxiii

## PART 1 GENERAL THEMES

### 1 Introduction

3

Why Write This Book? / 3

Doesn't This Book Just Help the Criminals? / 4

Who Is the Book Aimed At? / 5

### 2 Origins and Context of Counterfeiting in Healthcare

7

Background and Nature of the Threat / 7

R&D Costs, Patent Life, and the Profit Imperative / 9

A Low Cost, High Profit Business / 10

Research and Development / 10

Regulatory Approval / 10

Manufacturing / 11

Packaging / 11



Marketing / 11	
Logistics / 12	
Permissive Legal Environment / 12	
Role of the Internet / 13	
Global Growth of Counterfeiting / 14	
<b>3 A Snapshot of the Problem</b>	<b>15</b>
Case Study: Malaria / 18	
<b>4 Risks and Costs of Counterfeit Pharmaceuticals</b>	<b>21</b>
Risks and Costs for Consumers / 21	
The Drugs Do Not Work / 21	
Toxic Products / 23	
Fear and Mistrust of the Medical Profession / 24	
Risks and Costs for Businesses / 24	
Revenue Loss / 24	
Brand Erosion / 28	
Litigation / 30	
Loss of Public Trust / 30	
Risks and Costs for Governments / 31	
Public Concern / 31	
Increased Social and Healthcare Costs / 32	
Tension between Affordability and Quality / 34	
Increased Regulatory Costs / 34	
<b>5 Anti-Counterfeiting Definitions</b>	<b>35</b>
Terminology and General Principles / 36	
Counterfeiting / 38	
Diversion / 45	
Parallel Trade and Re-Importation / 46	
<b>6 Protecting and Educating Consumers</b>	<b>49</b>
Consumer Behavior / 49	
Engagement with the Consumer / 50	
Engaging Through Social Media / 51	

Social Networking and Blogging as Anti-Counterfeiting Tools / 52

Consumer-Focused Authentication Technology / 54

Cultural Sensitivity / 55

## **7 Business Risks and Strategy 57**

Establishing a Baseline and Prioritizing At-Risk Products / 59

Doing the Simple Things / 60

Used Manufacturing Equipment / 61

Layering of Countermeasures / 62

Information Management and “Need-To-Know” / 62

Integration with Corporate Strategy / 63

## **8 Government Issues 65**

Legal Framework / 66

Link with Reimbursement and Social Healthcare / 68

Law Enforcement Issues / 69

Data Mining / 69

Money Transfer and Credit Cards / 70

Internet Service Providers and Search Engines / 71

## **9 Intellectual Property and Anti-Counterfeiting 73**

Establishing Ownership of Intellectual Property Rights (IPR) / 74

Patents / 74

Patenting of Security Technologies / 75

Trademarks / 75

Online Intellectual Property / 78

Criminal Prosecution *Versus* Civil Suit / 79

## **10 Traceability or Authentication? 81**

## PART 2 AUTHENTICATION

- 11 What Is Authentication? 87**
  - Digital *Versus* Sensory Authentication / 88
  - Types of Authentication Technologies / 89
  - International Standards and Norms / 91
- 12 Authentication of the Person 93**
- 13 Authentication of Bulk Products 97**
- 14 On-Dose and In-Dose Authentication 103**
  - On-Dose Features / 104
  - In-Dose Features / 106
  - Regulatory Reporting / 109
  - Labeling and Disclosure of On-Dose and In-Dose Approaches / 110
  - Concealment of Identity / 110
  - On-Product and In-Product Approaches Aimed at Consumers / 111
  - Formulation Additives in Products other than SODFs / 112
- 15 Analytical Detection of Counterfeit Dosage Forms 113**
  - Simple Chemical and Physical Analysis Methods / 114
    - Colorimetry / 115
    - Hardness and Dissolution Tests / 115
    - Thin Layer Chromatography (TLC) / 116
    - Ultraviolet and Visible Spectroscopy / 117
  - Laboratory-Based Methods / 118
    - Atomic Absorption Spectrophotometry (AAS) / 118
    - X-ray Techniques / 119
    - Nuclear Magnetic Resonance (NMR) Spectroscopy / 119
    - Mass Spectrometry (MS) / 120
    - Gas Chromatography (GC) / 120

Liquid Chromatography (LC) / 121	
Capillary Electrophoresis (CE) / 121	
Forensic Palynology / 121	
Non-Destructive Methods / 123	
X-ray Diffraction / 123	
Infrared Spectroscopy / 123	
Fourier Transform Infrared (FTIR) Spectroscopy / 124	
Near-Infrared (NIR) / 125	
Raman Spectroscopy / 125	
Terahertz Imaging / 126	
Conclusions on the Analysis of Dosage Forms / 126	
<b>16 The Role of Packaging</b>	<b>127</b>
Packaging Design / 128	
Being Just Slightly Better than the Opposition / 130	
Security Features on Packaging / 131	
Integration into Packaging: Bulk Packaging Material at Source / 131	
Integration into Packaging: By Design Complexity / 132	
Addition to Packaging: Labels, Printed Packaging, etc. / 132	
<b>17 Printing Technologies</b>	<b>135</b>
Offset Lithography / 135	
Flexography / 136	
Gravure / 136	
Screen Printing / 137	
Laser Printing / 137	
Cliché or Pad Printing / 138	
Embossing and Debossing / 138	
Laser Engraving / 138	
Inkjet Printing / 138	
Some Technical Considerations / 140	



How Much Surface Area Is Available for the Feature? / 140	
What Is the Budget? / 141	
Is the Product Surface Flat or Curved? / 141	
Is the Product Orientation Predictable and Constant? / 142	
How Much Time Is Available? / 142	
Direct Application onto Packaging <i>Versus</i> Use of Labeling / 143	
<b>18 Security Labels</b>	<b>145</b>
Adhesive / 146	
Frangibility / 147	
Security Cuts and Perforation / 148	
Voiding / 148	
Alignment / 149	
General Considerations / 149	
Label Reconciliation and Storage Conditions / 151	
<b>19 Holograms and DOVIDS</b>	<b>153</b>
Types of Holograms / 154	
Other Optically Variable Devices / 156	
<b>20 Specialty Inks</b>	<b>159</b>
Colorshift Inks / 160	
Other Security Inks / 161	
Iridescent / 161	
Metallic / 162	
Fluorescent / 162	
Bi-fluorescent / 162	
Thermochromic / 163	
Photochromic / 163	
Coin Reactive / 163	
Microstructured Taggants / 163	

<b>21 Covert Taggants and Forensic Markers</b>	<b>165</b>
Infrared-Absorbing Inks / 165	
Forensic Markers / 166	
Isotopic Tags / 167	
DNA Markers / 167	
Antibody Systems / 168	
X-Ray Detection of Specific Added Elements / 168	
Other Markers / 168	
<b>22 General Conclusions on Printed Packaging and Security Labels</b>	<b>169</b>
Layering / 169	
Guidelines / 170	
Flexibility and Vigilance / 170	
<b>23 Security of Primary Packaging</b>	<b>173</b>
Contact with Dosage Form / 173	
Types of Primary Packaging / 175	
Blister Packs / 175	
Wallets, Carded Blisters, Compliance-Prompting Packaging, etc. / 179	
Strip Packs, Sachets, and Pouches / 180	
Bottles or Jars / 181	
Tubes / 183	
Vials and Ampoules / 184	
Other Dosage Forms / 187	
Syringes / 187	
Inhalers and Related Devices / 187	
Implantable Drug-Containing Devices / 189	
Equipment and Consumables for Diagnostic Products / 189	
Medical Devices / 190	
Analytical Considerations for Primary Packaging / 191	



<b>24 Security of Secondary Packaging</b>	<b>193</b>
Role of Secondary Cartons / 193	
Outsourced or In-House Application / 196	
Outsourced Security Features / 198	
In-House Security Application / 198	
Planning Ahead / 199	
Tamper-Evidence: Seals, Shrink Wraps, Pack Closures, and Adhesive / 200	
Definitions / 200	
Snap-Off Caps / 200	
Glued End-Flaps / 201	
Seals / 201	
Induction Seals / 203	
Shrink Wrap and Tear Tape / 203	
<b>25 Analytical Methods for Packaging</b>	<b>205</b>
Visual Inspection (Visible Light) / 206	
Other Optical Methods (UV, IR, Polarized Light) / 207	
Other Methods / 207	
<b>26 Security of Other Packaging Types</b>	<b>209</b>
Drug-Device Combinations / 209	
Patient Information Leaflets and Labels / 211	
Other Documentation / 212	
Certificates of Analysis, Import Licenses, etc. / 212	
Prescriptions / 213	
Reimbursement / 213	
<b>27 Bulk Packaging and Transport Security</b>	<b>215</b>
Theft of Cargo from Trucks and Warehouses / 216	
Vigilance / 218	
Information Management / 218	
Training / 218	
Other Factors / 219	

Technology Approaches: RFID and GPS /	219
Radio Frequency Identification (RFID) Technology /	219
Global Positioning System (GPS) Technology /	220

## **PART 3 PRODUCT TRACKING**

<b>28 Rationale for Pharmaceutical Tracking</b>	<b>225</b>
<b>29 Tracking Technologies</b>	<b>231</b>
Serial Numbers /	232
Linear Bar Codes /	234
Matrix Codes /	234
2D Codes and Mobile Phones /	236
Technical Issues with 2D Codes /	237
Radio Frequency Identification (RFID) /	238
Mobile Phones /	242
Other Tracking Technologies /	244
Applicability of Tracking Systems Worldwide /	245
<b>30 Data Format, Generation, and Storage</b>	<b>247</b>
Serialization /	247
Randomization /	250
Pedigree/ePedigree /	251
Track and Trace /	253
Fingerprinting /	254
Physical Authentication + Digital Tracking = Enhanced Security /	256
<b>31 Management of Packaging Hierarchy</b>	<b>257</b>
Inference Approaches /	257
“Bookend” Approaches /	262
Batch Level Traceability Versus Full Serialization /	266

Digital Signatures / 266

Supply Chain Benefits / 266

## **32 Geographical Perspectives**

**269**

U.S. State Laws / 269

California / 270

Federal Initiatives in the United States / 271

Europe / 273

The Concept of "Medicrime" / 275

European Committee on Crime Problems (CDPC) / 275

Purpose / 276

Scope / 276

Definitions / 276

Manufacturing of Counterfeits / 278

Supplying, Offering to Supply, and Trafficking  
in Counterfeits / 278

Falsification of Documents / 279

Similar Crimes Involving Threats to Public Health / 279

Aiding or Abetting and Attempt / 279

Jurisdiction / 280

Corporate Liability / 281

Sanctions and Measures / 281

Aggravating Circumstances / 282

Criminal Investigations / 282

Cooperation and Information Exchange / 283

Measures for Prevention / 283

Measures for Protection / 284

International Cooperation / 284

Monitoring Mechanism / 284

EFPIA Pilot Coding Project / 285

India / 287

Malaysia Meditag<sup>™</sup> System / 288

Turkey / 289

Brazil / 290



<b>33 Product Tracking in Other Industries</b>	<b>291</b>
Excise Products: Tobacco and Alcohol /	291
Food and Beverage /	292
Toys /	293
Conclusions /	294
<b>34 Supply Chain Security Processes</b>	<b>295</b>
General Security /	295
Forward Logistics /	296
Reverse Logistics: Returns and Customer Complaints /	297
Insider Fraud /	298
Security of Security Materials /	301
Security of Evidence /	302
<b>35 Implementing Anti-Counterfeiting Initiatives—Practical Issues</b>	<b>303</b>
How to Work Together: Getting the Best from Security Partnerships /	303
What Do Pharmaceutical Companies Need? /	304
What Do Security Suppliers Need? /	305
What Do Print and Packaging Suppliers Need? /	306
General Observations on Business Models for Product Security /	307
Unit Fee Pricing /	308
Commodity Pricing /	308
Insurance Premium /	309
Other Pharmaceutical Service Industries /	309
<b>PART 4 CONCLUSIONS AND THE FUTURE</b>	
<b>36 Where Do We Go from Here?</b>	<b>313</b>
Future Scenario: Risk of Inaction /	313

Future Scenario: Risk of Incomplete Action / 314

Future Scenario: Risk of Inappropriate Action / 314

Future Policy Approaches / 315

Future Authentication Approaches / 317

Future Traceability Approaches / 318

Global Standards, Worldwide Tracking / 318

RFID / 319

GPS / 319

### **37 New Models, New Approaches**

**321**

Non-Technological Approaches / 322

Lack of Availability of Genuine Drugs / 323

Huge Profit Potential / 323

Low Entry Costs / 324

Law Enforcement Issues / 324

Legal Approaches / 324

Conclusions / 325

### **38 Selected Examples from Around the World**

**329**

Argentina / 329

Brazil / 330

Canada / 330

China / 330

European Union / 331

India / 331

Laos and Southeast Asia / 331

Nigeria / 331

Russia / 332

Uganda/East Africa / 332

United Kingdom / 333

United States / 333

## PART 5 FURTHER RESOURCES

### A PATIENT'S GUIDE TO AVOIDING COUNTERFEIT DRUGS 337

Do I Need This Particular Medication? / 337

Is My Desired Drug Approved and Available  
in My Country? / 338

Are My Drug Sources and Methods  
of Purchase Safe? / 338

What Does the Packaging Look Like? / 339

What Does the Product Itself Look Like? / 340

When Taking the Drug / 341

After Taking the Drug / 341

### NOTES AND REFERENCES 343

### GLOSSARY 363

### INFORMATION SOURCES 379

General Readership / 379

Specialist Readership / 380

News / 381

Education / 381

Organizations / 381

### DRUG REGULATORS 385

### INDEX 391